OPHLY:OTCMKTS
Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
4,74Â USD
arrow_upward
+0,64%(+0,030) 1G
9 ott, 16:00:00 GMT-4 · USD
search
Tutti i simboli
| Simbolo | Prezzo | Cambio | % di cambio |
|---|
insights_autoGenerazione degli insight principali per OPHLY in corso…
Apertura
4,71Â USD
Massimo
4,78Â USD
Minimo
4,71Â USD
Cap. mercato
1,13Â Bln
Vol. medio
58,90K
Volume
0,00
Max 52 sett.
5,75Â USD
Min 52 sett.
3,81Â USD
Beta
0,21
Azioni in circolazione
1,50Â Mld
N. di dipendenti
4K
Apertura
4,71Â USD
Massimo
4,78Â USD
Minimo
4,71Â USD
Cap. mercato
1,13Â Bln
Vol. medio
58,90K
Volume
0,00
Max 52 sett.
5,75Â USD
Min 52 sett.
3,81Â USD
Beta
0,21
Azioni in circolazione
1,50Â Mld
N. di dipendenti
4K
Articoli giornalistici
Da fonti web e partner giornalistici
Simply Wall Street
·
2 giorni fa
How Biohaven Licensing Deal At Ono Pharmaceutical Stock Has Changed Its Investment Story
Profilo
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
Informazioni su Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
CEOGyo Sagara | Gyo Sagara
Dipendenti4,21K
Data di fondazione1717
SedeOsaka, Prefettura di Osaka, Giappone
Settore-
Sito webono-pharma.com